Ivarmacitinib free base | CAS# 1445987-21-2 | JAK inhibitor

MedKoo Cat#: 533297 | Name: Ivarmacitinib free base

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Ivarmacitinib, also known as SHR0302, is a novel potent JAK inhibitor which blocks JAK/STAT3 signaling, suppresses proliferation, migration and collagen production, and induces the apoptosis of hepatic stellate cells. SHR0302 may attenuate the severity of AA rats, partially through reducing Th17 function and total B cell proportion by inhibiting JAK1-STAT3 phosphorylation.

Chemical Structure

Ivarmacitinib free base

CAS#1445987-21-2 (free base)

Theoretical Analysis

MedKoo Cat#: 533297

Name: Ivarmacitinib free base

CAS#: 1445987-21-2 (free base)

Chemical Formula: C18H22N8O2S

Exact Mass: 414.1586

Molecular Weight: 414.49

Elemental Analysis: C, 52.16; H, 5.35; N, 27.03; O, 7.72; S, 7.73

Price and Availability

Size	Price	Availability
25mg	USD 550.00	2 Weeks
50mg	USD 950.00	2 Weeks
100mg	USD 1,650.00	2 Weeks
200mg	USD 2,650.00	2 Weeks
500mg	USD 4,650.00	2 Weeks
1g	USD 7,650.00	2 Weeks
2g	USD 11,950.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

1445987-21-2 (free base) 1639419-51-4 (sulfate) 1639419-53-6 (HCl)

Synonym

Ivarmacitinib sulfate; Ivarmacitinib; SHR0302; SHR-0302; SHR 0302

IUPAC/Chemical Name

(3aR,5s,6aS)-N-(3-Methoxy-1,2,4-thiadiazol-5-yl)-5-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)hexahydrocyclopenta[c]pyrrole-2(1H)-carboxamide

InChi Key

DNBCBAXDWNDRNO-GDNZZTSVSA-N

InChi Code

InChI=1S/C18H22N8O2S/c1-25(15-13-3-4-19-14(13)20-9-21-15)12-5-10-7-26(8-11(10)6-12)18(27)23-17-22-16(28-2)24-29-17/h3-4,9-12H,5-8H2,1-2H3,(H,19,20,21)(H,22,23,24,27)/t10-,11+,12+

SMILES Code

O=C(N1C[C@]2([H])[C@](C[C@@H](N(C)C3=C4C(NC=C4)=NC=N3)C2)([H])C1)NC5=NC(OC)=NS5

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 414.49 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Fu M, Luo L, Feng S, Lin H, Lu Z, Gu F, Fan Y, Wu B, Huang J, Shen K. Effect of SHR0302 on the Pharmacokinetics of CYP3A4, CYP2C8, CYP2C9, and CYP2C19 Probe Substrates in Healthy Volunteers: A Cocktail Analysis. Br J Clin Pharmacol. 2023 Jul 19. doi: 10.1111/bcp.15856. Epub ahead of print. PMID: 37464978. 2: Ertus C, Scailteux LM, Lescoat A, Berthe P, Auffret V, Dupuy A, Oger E, Droitcourt C. Major adverse cardiovascular events in patients treated with oral Janus kinase inhibitors for atopic dermatitis: a systematic review and meta- analysis. Br J Dermatol. 2023 Jul 6:ljad229. doi: 10.1093/bjd/ljad229. Epub ahead of print. PMID: 37410552. 3: Caso F, Costa L, Triggianese P, Maione F, Bertolini N, Vastarella M, Chimenti MS, Tasso M. Recent developments for new investigational JAK inhibitors in psoriatic arthritis. Expert Opin Investig Drugs. 2023 May;32(5):361-371. doi: 10.1080/13543784.2023.2207737. Epub 2023 May 3. PMID: 37096862. 4: Goetsch A, D'Amico F, Allocca M, Fiorino G, Furfaro F, Zilli A, Parigi TL, Radice S, Peyrin-Biroulet L, Danese S. Advances in pharmacotherapy for ulcerative colitis: a focus on JAK1 inhibitors. Expert Opin Pharmacother. 2023 May;24(7):849-861. doi: 10.1080/14656566.2023.2200931. Epub 2023 Apr 11. PMID: 37038911. 5: Zhou C, Yang X, Yang B, Yan G, Dong X, Ding Y, Fan W, Li L, Yang D, Fang H, Ji C, Cheng H, Zhang S, Goh AH, Liu R, Gu X, Weng Z, Foley P, Sinclair R, Zhang J. A Randomized, Double-Blind, Placebo-Controlled Phase II Study to Evaluate the Efficacy and Safety of Ivarmacitinib (SHR0302) in Adult Patients with Moderate to Severe Alopecia Areata. J Am Acad Dermatol. 2023 Apr 3:S0190-9622(23)00527-3. doi: 10.1016/j.jaad.2023.02.063. Epub ahead of print. PMID: 37019385. 6: Zhang Z, Gao X, Zhang P, Li Y, Fu M, Lin H, Feng S, Shen K, Yu G, Li X. Effect of CYP3A4 induction and inhibition on the pharmacokinetics of SHR0302 in healthy subjects. Br J Clin Pharmacol. 2023 Aug;89(8):2561-2568. doi: 10.1111/bcp.15733. Epub 2023 Apr 17. PMID: 37005376. 7: Ge X, Ma S, Yan S, Wu Y, Chen C, Tang C, Zhan Y, Bian YC, Shen K, Feng S, Gao X, Zhong D, Zhang H, Miao LY, Diao XX. Mass balance study of [14C]SHR0302, a selective and potent JAK1 inhibitor in humans. Xenobiotica. 2023 Feb;53(2):69-83. doi: 10.1080/00498254.2023.2176267. Epub 2023 Feb 12. PMID: 36745485. 8: Li B, Li N, Goh AH, Cao H, Irwin MW, Tong X, Wang J, Wu X, Zhang J, Pu D. A Phase I Study to Evaluate the Safety and Pharmacokinetics of SHR0302 Base Ointment in Healthy Adult Volunteers. Skin Pharmacol Physiol. 2023;36(2):76-86. doi: 10.1159/000528739. Epub 2022 Dec 29. PMID: 36580897. 9: Chen TL, Lee LL, Huang HK, Chen LY, Loh CH, Chi CC. Association of Risk of Incident Venous Thromboembolism With Atopic Dermatitis and Treatment With Janus Kinase Inhibitors: A Systematic Review and Meta-analysis. JAMA Dermatol. 2022 Nov 1;158(11):1254-1261. doi: 10.1001/jamadermatol.2022.3516. PMID: 36001310; PMCID: PMC9403856. 10: Chen B, Zhong J, Li X, Pan F, Ding Y, Zhang Y, Chen H, Liu F, Zhang Z, Zhang L, Drozda R, Oliinyk O, Goh AH, Chen X, Sun X, Rubin DT, Sandborn WJ, Chen M. Efficacy and Safety of Ivarmacitinib in Patients With Moderate-to-Severe, Active, Ulcerative Colitis: A Phase II Study. Gastroenterology. 2022 Dec;163(6):1555-1568. doi: 10.1053/j.gastro.2022.08.007. Epub 2022 Aug 10. PMID: 35963369. 11: Ding LK, Chen Y, Liu MY, Gao XH, Ren DJ, Diao QB, Yang L, Wen AD, Wang JW. Quantification of SHR0302 in human plasma by UPLC-MS/MS and application to a pharmacokinetic study. Biomed Chromatogr. 2022 Nov;36(11):e5474. doi: 10.1002/bmc.5474. Epub 2022 Aug 11. PMID: 35916260. 12: Zhao Y, Zhang L, Ding Y, Tao X, Ji C, Dong X, Lu J, Wu L, Wang R, Lu Q, Goh AH, Liu R, Zhang Z, Zhang J. Efficacy and Safety of SHR0302, a Highly Selective Janus Kinase 1 Inhibitor, in Patients with Moderate to Severe Atopic Dermatitis: A Phase II Randomized Clinical Trial. Am J Clin Dermatol. 2021 Nov;22(6):877-889. doi: 10.1007/s40257-021-00627-2. Epub 2021 Aug 9. PMID: 34374027; PMCID: PMC8351769. 13: Sun X, He Q, Yang J, Wang A, Zhang F, Qiu H, Zhou K, Wang P, Ding X, Yuan X, Li H, Zhang Y, Song X. Preventive and Therapeutic Effects of a Novel JAK Inhibitor SHR0302 in Acute Graft-Versus-Host Disease. Cell Transplant. 2021 Jan- Dec;30:9636897211033778. doi: 10.1177/09636897211033778. PMID: 34269100; PMCID: PMC8287347. 14: Yang AY, Liu JQ, Cai YN, Fang MY, Yang L, Chen M, Li B, Xiao ZJ. [The anti- proliferative and anti-inflammatory mechanisms of JAK1 inhibitor SHR0302 versus Ruxolitinib in SET2 cell line and primary cells]. Zhonghua Xue Ye Xue Za Zhi. 2019 Dec 14;40(12):1003-1007. Chinese. doi: 10.3760/cma.j.issn.0253-2727.2019.12.006. PMID: 32023730; PMCID: PMC7342687. 15: Gu YJ, Sun WY, Zhang S, Li XR, Wei W. Targeted blockade of JAK/STAT3 signaling inhibits proliferation, migration and collagen production as well as inducing the apoptosis of hepatic stellate cells. Int J Mol Med. 2016 Sep;38(3):903-11. doi: 10.3892/ijmm.2016.2692. Epub 2016 Jul 26. PMID: 27460897. 16: Wu H, Yan S, Chen J, Luo X, Li P, Jia X, Dai X, Wang C, Huang Q, Liu L, Zhang Y, Zhou A, Chang Y, Zhang L, Wei W. JAK1-STAT3 blockade by JAK inhibitor SHR0302 attenuates inflammatory responses of adjuvant-induced arthritis rats and decreases Th17 and total B cells. Joint Bone Spine. 2016 Oct;83(5):525-32. doi: 10.1016/j.jbspin.2015.09.002. Epub 2016 Jan 29. PMID: 26832189.